PCV40 VARIATION OF COST-TO-CHARGE RATIO FOR CABG PATIENT BY HOSPITAL TYPE OVERTIME  by Huang, X et al.
A130 Abstracts
PCV37
SURVEY OF PHYSICIAN ATTITUDES AND PRACTICES IN
LIPID LOWERING MANAGEMENT
Lewis BE1, Rosen J2, Roselli A3, Goldberg RJ4
1AstraZeneca, Worcester, MA, USA, 2ProHealth Physicians, Inc, Bristol,
CT, USA, 3ProHealth Physicians, Farmington, CT, USA, 4University of
Massachusetts Medical School, Worcester, MA, USA
OBJECTIVES: While published guidelines for managing hyper-
lipidemia are well publicized, many patients either are not
treated or managed suboptimally. This study examined physi-
cians’ knowledge, attitudes and practices in managing primary
care patients with elevated serum lipid levels. METHODS: An
online questionnaire was developed, pilot tested, and adminis-
tered to 98 primary care physicians with patients at varying risk
for coronary heart disease (CHD.) The questionnaire was admin-
istered during a two week period. Questions assessed physician’s
knowledge of current national guidelines for managing patients
with hyperlipidemia, use of various lipid lowering therapies,
lifestyle interventions to lower serum lipids, use of national
guidelines, and treatment practice for patients at varying risk for
CHD. Questions used a 5 point Likert scale (with 1 indicating
very important and 5 of little to no importance). RESULTS: The
questionnaire had an 80% response rate. Most physicians
reported following published national cholesterol guidelines all
(15%) or most (77%) of the time. Physicians perceived them-
selves to be very knowledgeable about current published national
guidelines for the management of elevated serum cholesterol
levels (53%), lifestyle interventions to lower serum lipids (50%),
and lipid lowering therapies (49%); they were considerably less
knowledgeable (19%) about costs of lipid lowering medications.
Major concerns with the use of published national guidelines
included lack of patient compliance (moderately to strongly
agree) (72%), and lack of time to adequately use guidelines
during ofﬁce visits (22%). CONCLUSIONS: Despite physician
guideline awareness, achieving desirable serum lipid levels in the
patient population remains an elusive target. Current provider
education efforts are not sufﬁcient. As more managed care orga-
nizations and group practices implement electronic medical
records, the use of evidence based treatment algorithms should
result in better management of cardiovascular risk factors,
including elevated LDL levels, in general practice populations as
well as targeted high risk groups.
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INITIAL PHARMACEUTICAL TREATMENT OF SIMPLE
HYPERTENSION
Zhang K,Young C
Caremark, Scottsdale, AZ, USA
OBJECTIVES: The Seventh Report of the Joint National Com-
mittee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure (JNC 7) recommended diuretics as ﬁrst-line
treatment for plan participants with simple hypertension in
2003. This study evaluated initial pharmaceutical treatment for
plan participants diagnosed with simple hypertension.
METHODS: The authors selected Caremark plan participants
from integrated, deidentiﬁed pharmacy and medical claims data
who were diagnosed with hypertension between Oct. 10, 2003,
and March 31, 2004. Plan participants had to be eligible for
pharmacy and medical beneﬁts one year prior and one month
post diagnosis, not have a prior diagnosis for hypertension, and
not be diagnosed with a comorbid condition during the 11-
month period studied. RESULTS: In the month following diag-
nosis, 2033 plan participants ﬁlled a prescription for at least one
antihypertensive drug. Most of these plan participants were
treated by primary-care physicians (84.9%). The remainder were
treated by either by a cardiologist (2.3%) or some other type of
specialist (12.8%). Of all those studied, 41.2% were initiated on
a diuretic either as monotherapy or in combination with one of
the other drugs. Those starting with diuretic monotherapy rep-
resented 26.3%, while 30.9% initiated therapy with a combina-
tion of antihypertensive drugs. The remaining 42.8% were
initiated on some other type of monotherapy. Of the plan par-
ticipants who initiated therapy with one antihypertensive, 31.8%
started with a diuretic, 21.7% with an ACE inhibitor, and 17.8%
with a beta-blocker. Of those prescribed a combination of drugs,
45.2% initiated on an ARB and diuretic, 34.9% on an ACE
inhibitor and diuretic. Overall, 63.69% started with generic ther-
apies and 36.31% with a brand drug. CONCLUSION: Only a
minority of plan participants diagnosed with simple hyperten-
sion, without complicating comorbid conditions, were pre-
scribed a diuretic monotherapy.
CARDIOVASCULAR DISEASE—Methods and Concepts
PCV39
PREDICTING ANTIHYPERTENSIVE DRUG UTILIZATION:AN
APPLICATION OF LATENT CLASS MODELS
Thiebaud P, Patel BV
MedImpact Healthcare Systems, Inc, San Diego, CA, USA
OBJECTIVES: To analyze patterns of antihypertensive drug uti-
lization and to forecast pharmacy utilization and costs in hyper-
tensive patients. METHODS: The sample consisted of 23,272
patients who were continuously eligible for drug beneﬁts for at
least 14 quarters. Utilization was recorded and summarized for
every quarter. The ﬁrst two quarters represented the baseline uti-
lization, and the following 12 quarters were used to determine
individual utilization trajectories. Patients were included in the
sample if they used antihypertensive drugs during the baseline
period. The sample was split into analysis and test sub-samples.
Model parameters developed in the analysis sample were used to
forecast utilization in the test sample. Utilization for the ﬁfth and
twelfth quarters was predicted based upon information gathered
from the previous quarter. The accuracy of the model was tested
by comparing predicted and actual outcomes. The analysis was
based on latent class models. Demographic characteristics, drug
beneﬁt details, and concurrent drugs served as covariates. Two
outcome variables were computed for each patient: the number
of prescriptions per quarter and the probability of exceeding a
certain cost threshold. RESULTS: For number of prescriptions,
the quarter-ahead forecasts were within 0.4 prescriptions of the
actual ﬁgures. For prescription expenditures greater than $150,
the difference between actual and estimated probabilities was
0.9% for the twelfth-quarter forecast and 4.4% for the ﬁfth-
quarter. Latent class models also accurately separated patients
into low/high cost groups and increasing/decreasing cost groups
by deﬁning cost and utilization trajectories for individual
patients. CONCLUSION: Latent class models produce accurate
forecasts that can be used to improve the management of hyper-
tensive patients. Compared to other forecasting techniques, these
models produce results that can be more easily understood by a
wide range of readers, a critical issue in outcomes research.
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VARIATION OF COST-TO-CHARGE RATIO FOR CABG
PATIENT BY HOSPITAL TYPE OVER TIME
Huang X1, Gondek K1, Smith P2
1Bayer Pharmaceuticals Corporation, West Haven, CT, USA, 2Duke
University Medical Center, Durham, NC, USA
OBJECTIVES: Cost of care is essential for burden of illness and
cost-effectiveness studies. However, collecting cost data is very
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difﬁcult. In traditional clinical trials challenges to completeness
and accuracy of cost data and protocol-induced bias may reduce
generalizability of results. “Real-world” trials are potentially
useful but few have been conducted. With readily available
claims data, the practical approach is to use cost-to-charge ratio
to estimate the dollar value of consumed resources. This paper
examines the characteristics and cost-to-charge ratio for CABG
patients by hospital and department over time. METHODS:
Premier data for 17,000 CABG patients from 187 US hospitals
between 2002 and 2004 were used. Hospital cost-to-charge
ratios were estimated with patient level total cost and charges at
discharge and within each department. Cost-to-charge ratio by
hospital type and location were assessed. RESULTS: Cost-
to-charge ratios were not associated with hospital bed size
although from 2002 to 2004, the ratios decreased ranging from
2% to 14% percent indicating improved efﬁciency for all hos-
pitals. The cost-to-charge ratio disparity between teaching and
non-teaching hospitals is shrinking over time (0.43 vs. 0.40 and
0.39 vs. 0.38 at year 2002 and 2004, respectively). The cost-to-
charge ratio gap between urban and rural hospitals remains over
time (0.48 vs. 0.40 at year 2002, 0.46 vs. 0.37 at year 2004).
With regard to departmental cost-to-charge ratio, they differ
greatly by hospital department and vary across hospitals. Except
for anesthesia, for teaching hospitals departmental cost-to-
charge ratios declined on average by 14% (4% to 28%) from
2002 to 2004. For non-teaching hospitals, changes over time
were mixed. For urban hospitals, departmental cost-to-charge
ratios had declining patterns similar to that of teaching hospi-
tals. CONCLUSIONS: Cost-to-charge ratio for CABG patients
varies by hospital type and these differences declined over time.
Appropriate cost-to-charge ratios must be used in order to
produce valid cost estimates.
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PROVISION OF DIET/NUTRITION AND EXERCISE
COUNSELING FOR PATIENTS WITH DYSLIPIDEMIA BY
AMBULATORY CARE PHYSICIANS IN THE UNITED STATES
Lee LJ, Nichol MB
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: First, estimate the prevalence of diet/nutrition
(DN) and exercise counseling (EC) in patients with dyslipidemia
during ambulatory care visits in the United States. Secondly,
compare the likelihood of receiving DN or EC across various
patient and physician characteristics. METHODS: The National
Ambulatory Medical Care Survey (NAMCS) data for 2000 and
2001 were merged to obtain cross-sectional nationwide estimates
of DN and EC. Dyslipidemia patients were identiﬁed by ICD-9
codes (272.XX). Sampling weights were provided by the
NAMCS and logistic regressions were used. RESULTS: A total
of 29.6 million (2-year average) visits in the U.S. had a diagno-
sis of dyslipidemia (n = 1620). Provision of DN was greater than
EC (37% and 25%, respectively). Men were statistically signiﬁ-
cantly more likely to receive DN and EC than women, after
adjusting for race and age (OR = 1.2 and 1.3, respectively). After
adjusting for race and gender, subjects aged 50–64 years were
more likely to receive DN than any other age group and subjects
aged 30–49 were more likely to receive EC than any other age
group. Compared to whites, blacks were 30% and 10% more
likely to receive DN and EC, respectively, after adjusting for age
and gender. It was found that self-paying subjects were more
likely to receive EC (OR = 1.2, p = 0.003) but less likely to
receive DN (OR = 0.72, p = 0.0002) than subjects with private
insurance. Physicians located in the West provided greater pro-
visions of DN and EC when compared to physicians located in
other parts of the United States (OR = 2.2 and 1.5, respectively).
Compared to internists or cardiologists, family medicine physi-
cians provided more DN and EC (p < 0.0001). CONCLUSION:
Over two years, provisions of DN and EC were relatively low.
More efforts in providing these preventative measures are 
warranted.
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PREDICTING HIGH COSTS IN CALIFORNIA MEDICAID
PATIENTS WITH CARDIOVASCULAR DISEASE (CVD)
Nichol MB1, Dow T1, Knight TK1, Gause D2,Wong KS2,Yu AP1
1University of Southern California, Los Angeles, CA, USA, 2Novartis
Pharmaceuticals, East Hanover, NJ, USA
OBJECTIVES: To predict high-risk patients with cardiovascular
disease (CVD) over a 1, 2, and 3 year time period. Good pre-
diction models will enable health care providers to target high
risk patients who would most beneﬁt from intervention pro-
grams designed to improve CVD patient outcomes. METHODS:
Using classiﬁcation and regression tree (C&RT) analysis from
AnswerTree (SPSS 3.0), risk models were developed using 
California Medicaid (Medi-Cal) medical and pharmaceutical
claims data for 62,154 patients with a diagnosis of CVD. Vari-
ables deﬁned for the 6-month pre-period were used to predict
year 1, year 2, and year 3 total costs. To determine the predic-
tive ability of the model, we designated high cost patients as
those with total costs of greater than $10,000, and low cost
patients as those with less than $10,000. RESULTS: Outpatient
cost (of approximately $3600, >1 SD above the median) in the
six months prior to diagnosis was the most common split. Other
contributing factors were patient comorbidities, including Other
Neurological Disorders (p < 0.01), Deﬁciency Anemias (p <
0.01), and Hypertension (p < 0.01). Results for years 2 and 3
were similar to year 1 ﬁndings. With further examination of the
data, we found that the small group of high cost patients at Year
1 continue to be high cost patients in the subsequent years,
although nearly 14.5% drop out at year 2 and 14.5% dropout
from year 2 to year 3. 35% of the sample was correctly grouped
into the high-cost branch, while 98% of the low-cost subjects
were correctly grouped into the low-cost branch. CONCLU-
SIONS: C&RT is a useful method in predicting high risk
patients. As demonstrated in this sample, patients incurring high
costs were signaled through outpatient utilization, and were cor-
rectly identiﬁed with a sensitivity of 35% and a speciﬁcity of
98%.
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AN EMPIRICAL EVALUATION OF THE EXPECTED VALUE OF
PERFECT INFORMATION
Lundy J, Davies GM, Cook JR
Merck and Co, Blue Bell, PA, USA
OBJECTIVE: The Expected Value of Perfect Information (EVPI)
is becoming an increasing valuable tool to assist healthcare deci-
sion makers with their choices of new healthcare technologies.
Although the use of EVPI in healthcare decision making is on
the rise the study of its properties has received little attention.
This study will evaluate the properties of the EVPI in the context
of a currently published model for a cholesterol lowering
therapy. METHODS: The properties of the EVPI were studied
using a Markov chain model that evaluated the cost-effective-
ness of ezetimibe co-administration with statin therapy vs statin
titration (Cook et al. 2004). Simulations of the model were run
for iterations of size 1000, 10,000 and 100,000. Baseline deci-
sions were evaluated for blocks of 1000 iterations and the
percent of correct optimal decisions as well as the mean and stan-
dard deviation for the net beneﬁts were tabulated within each
block. RESULTS: The estimated EVPI for 1000, 10,000 and
